2-Deoxy-2-[18F]fluoro-d-glucose positron emission tomography demonstrates target inhibition with the potential to predict anti-tumour activity following treatment with the AKT inhibitor AZD5363

Molecular Imaging and Biology

Volumn 15, Issue 4, 2013, Pages 476-485

  Maynard, Juliana ^a   Ricketts, Sally Ann ^a   Gendrin, Christelle ^a   Dudley, Phillippa ^a   Davies, Barry R ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

18F FDG PET; AKT; Biomarker; Personalised medicine

Indexed keywords

AZD 5363; FLUORODEOXYGLUCOSE F 18; GLUCOSE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ENZYME ACTIVATION; FEMALE; GLIOBLASTOMA; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CANCER; MOUSE; MULTIPLE DRUG DOSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MICE; MICE, NUDE; PHOSPHORYLATION; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; PYRROLES; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MAMMALIA; MUS; MUS MUSCULUS;

EID: 84880325698     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-013-0613-3     Document Type: Article

References (36)

1. Luo J, Manning BD, Cantley LC (2003) Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4:257-262
2. Marone R, Cmiljanovic V, Giese B, Wymann MP (2008) Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 1784:159-185
3. Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27:5497-5510
4. Markman B, Dienstmann R, Tabernero J (2010) Targeting the PI3K/AKT/mTOR pathway beyond rapalogs. Oncotarget 1:530-543
5. Hirai H, Sootome H, Nakatsuru Y, Miyama K et al (2010) MK-2206, an allosteric AKT inhibitor, enhances tumour efficacy by standard chemotherapeutic agents or molecular targeted drugs in-vitro and in-vivo. Mol Cancer Ther 9:1956-1967
6. Davies BR, Greenwood H, Dudley P, Crafter C et al (2012) Preclinical Pharmacology of AZD5363: an inhibitor of AKT: pharmacodynamics, antitumour activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther 11:873-887
7. Wahl RL, Zasadny K, Helvie M, Hutchins GD et al (1993) Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 11:2101-2111
8. Kidd EA, Siegel BA, Dehdashti F, Grigsby PW (2007) The standardised uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 15:1738-1744
9. Larson SM, Schwartz LH (2006) 18F-FDG PET as a candidate for "Qualified Biomarker": functional assessment of treatment response in oncology. J Nucl Med 47:901-903
10. 18FDG Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39:2012-2020
11. Sunaga N, Oricuhi N, Kaira K, Yanagitani N et al (2008) Usefulness of FDG-PET for early prediction of the response to Gefitinib in non small cell lung cancer. Lung Cancer 59:203-210
12. Bendell JC, Rodon J, Burris HA, de Jonge M et al (2012) Phase 1, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumours. J Clin Oncol 30:282-290
13. Young H, Baum R, Cremerius U, Herholz K et al (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organisation for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35:1773-1782
14. Roe K, Aleksandersen TB, Kristian A, Nilsen LB et al (2010) Pre-clinical dynamic 18F-FDG PET - tumour characterization and radiotherapy response assessment by kinetic compartment analysis. Acta Oncol 49:914-921
15. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 29:1261-1274
16. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R et al (2004) AKT stimulates aerobic glycolysis in cancer cells. Cancer Res 64:3892-3899
17. 18F Fluorodeoxyglucose positron emission tomography correlates with AKT pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol 27:2697-2704
18. 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus. J Nucl Med 50:1815-1819
19. Bao Q, Newport D, Chen M, Stout D et al (2009) Performance evaluation of the inveon dedicated PET preclinical tomograph based on the NEMA NU-4 standards. J Nucl Med 50:401-408
20. Gambhir S (2004) Quantitative assay development for PET. In: Phelps ME (ed) PET: molecular imaging and its biological applications. Springer-Verlag, Berlin Germany, pp 125-216
21. Laforest R, Sharp TL, Engelbach JA, Fettia NM et al (2005) Measurement of input functions in rodents: challenges and solutions. Nucl Med Biol 32:679-685
22. Nguyen QD, Perumal M, Waldman TA, Abogaye EO (2011) Glucose metabolism measured by [18F] fluorodeoxyglucose positron emission tomography is independent of PTEN/AKT status in human colon carcinoma cells. Transl Oncol 4:241-248
23. 18 F-FDG uptake in vivo in the human glioma xenograft model U87-MG. Mol Cancer Ther 8(supplement 1):A225
24. Wei LH, Su H, Hildebrandt IJ, Phelps ME et al (2008) Changes in tumour metabolism as readout for mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin Cancer Res 14:3416-3426
25. Nogova L, Gross SH, Dimitrijevic et al (2008). Pharmacodynamics of RAD001 measured by early FDG-PET in patients with recurrent NSCLC (abstract). J Clin Oncol 26(May 20 suppl): Abstract 14616
26. 18F-FDG PET. J Nucl Med 50:97S-105S
27. Benz MR, Czernin J, Allen Auebrach MS, Itap UD et al (2009) FDG-PET/CT imaging predicts histopathological treatment responses after the initial cycle of neoadjuvant therapy in high grade soft-tissue sarcomas. Clin Cancer Res 15:2856-2863
28. De Geus Oei LF, Vriens D, Van Laarloven HW, Van der Graaf WT et al (2009) Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med 50:543-554
29. Cheebsumon P, Velasquez LM, Hoekstra CJ, Hayes W et al (2011) Measuring response to therapy using 18F-FDG PET. Semi-quantitative and full kinetic analysis. Eur J Nucl Med Mol Imaging 38:832-842
30. Minn H, Leskinen-Kallio S, Lindholm P, Bergmani J et al (1993) 18F Flourodeoxyglucose uptake in tumours. Kinetic vs steady state methods with reference to plasma insulin. J Comput Assist Tomgr 17:115-123
31. Minn H, Zasadny KR, Quint LE, Wahl RL (1995) Lung cancer: reproducibility of quantitative measurements for evaluating 2[F18]-fluorodeoxyglucose uptake of PET. Radiology 196:167-173
32. Plathow C, Weber WA (2008) Tumour cell metabolism imaging. J Nucl Med 49(Suppl2):43S-63S
33. 18F-FDG distribution with regional expression of glucose transporters and hexokinase II in experimental tumour. J Nucl Med 46:675-682
34. Pugachev A, Ruan S, Carlin S, Larson SM et al (2005) Dependence of FDG uptake on tumour micro-environment. Int J Radiat Oncol Biol Phys 62:545-553
35. 18F-FDG kinetics in locally advanced breast cancer: correlation with tumour blood flow and changes in response to neoadjuvant chemotherapy. J Nucl Med 45:1829-1837
36. Phelps ME, Huang SC, Hoffman EJ, Selin MS et al (1999) Tomographic measurement of local cerebral glucose metabolic rate in humans with (F18) 2-flourodeoxyglucose: validation of method. Ann Neurol 6:371-388